Disclosed herein, inter alia, are compositions and methods useful for inhibiting reticulon 4 (RTN4).

Disclosed herein, inter alia, are compositions and methods useful for inhibiting reticulon 4 (RTN4).

The present invention relates to novel 5HT receptor modulators, such as compounds of the general Formula (I) and general Formula (II):

##STR00001##

or a pharmaceutically acceptable salt thereof. Methods of using the compounds include, for example, modulation of 5-hydroxytryptamine (5-HT) receptor subtypes, including 5-hydroxytryptamine 2A receptor and/or 5-hydroxytryptamine 2C receptor, and treatment of a condition or disease where the treatment is associated with the modulation of 5-hydroxytryptamine 2A receptor and/or 5-hydroxytryptamine 2C receptor.

The present invention relates to novel 5HT receptor modulators, such as compounds of the general Formula (I) and general Formula (II):

##STR00001##

or a pharmaceutically acceptable salt thereof. Methods of using the compounds include, for example, modulation of 5-hydroxytryptamine (5-HT) receptor subtypes, including 5-hydroxytryptamine 2A receptor and/or 5-hydroxytryptamine 2C receptor, and treatment of a condition or disease where the treatment is associated with the modulation of 5-hydroxytryptamine 2A receptor and/or 5-hydroxytryptamine 2C receptor.

Disclosed herein are dihydroceramide desaturase 1 (Des1) inhibitor compounds and compositions, which are useful in the treatment of diseases, such as metabolic, cardiovascular, fibrotic, autoimmune/chronic inflammatory diseases, cystic fibrosis, various cancers, neurodegenerative diseases, lipid storage disorders, and ischemia/reperfusion injury, where inhibition of Des1 is expected to be therapeutic to a patient. Methods of inhibition of Des1 activity in a human or animal subject are also provided.

Described herein are compounds, pharmaceutical compositions and medicaments that include such compounds, and methods of using such compounds to modulate transient receptor potential vanilloid 1 receptor (TRPV1) activity.

Described herein are compounds, pharmaceutical compositions and medicaments that include such compounds, and methods of using such compounds to modulate transient receptor potential vanilloid 1 receptor (TRPV1) activity.

An aspect of the present invention provides a monomer from which a polymer layer capable of keeping high display quality even in high temperature and high humidity environments can be formed. The monomer in an aspect of the present invention is a compound represented by P-Sp.sup.1-Z.sup.2-A.sup.1-(Z.sup.1-A.sup.2).sub.n1-Z.sup.3-Sp.sup.2-P: in the formula, P denotes the same or different radical polymerizable group; and at least one of Z.sup.1, Z.sup.2, and Z.sup.3 denotes NRCO or CONR group.

An aspect of the present invention provides a monomer from which a polymer layer capable of keeping high display quality even in high temperature and high humidity environments can be formed. The monomer in an aspect of the present invention is a compound represented by P-Sp.sup.1-Z.sup.2-A.sup.1-(Z.sup.1-A.sup.2).sub.n1-Z.sup.3-Sp.sup.2-P: in the formula, P denotes the same or different radical polymerizable group; and at least one of Z.sup.1, Z.sup.2, and Z.sup.3 denotes NRCO or CONR group.

Provided are a class of alkylphenol compounds and a preparation method therefor. Specifically provided are a new alkyl polyphenol compound as represented by chemical formula I, and a preparation method therefor and the use thereof in the treatment of metabolic syndrome.

##STR00001##